Abstract
Synovial fluid in patients may differ in molecular weight depending on the presence and degree of osteoarthritis. Treatment is not directed at this relationship. Patients with osteoarthritis of the knee with resting visual analogue scale (VAS) pain of >45 mm were included in a randomized, prospective, double-blind cohort followed for 16 weeks. Patients were randomized at baseline to receive a three intra-articular injection series with one of: dual molecular weight (DMW; 580–780 kDa + 1.2 to 2.0 million Da); low molecular weight (LMW; 500–730 kDa); high molecular weight (HMW; 6 million Da); or saline placebo over 3 weeks. Patients completed baseline assessment of rest and walking VAS pain (primary efficacy variable), collection of a 5-point categorical global satisfaction score, and record of adverse events. Two-hundred and twenty-five patients (age 68 ± 8 y) were screened and 200 were randomized to one of the four groups. There were no differences at baseline between groups. At 4, 12 and 16 weeks, respectively, walking VAS pain was significantly improved in all treatment groups vs. placebo: DMW (79.6%, p < 0.001; 85.6, p < 0.001; 89.3%, p < 0.001); LMW (73.6%, p < 0.001; 76.4, p < 0.001; 81.3%, p < 0.001) and HMW (69.1%, p < 0.001; 81.0, p < 0.001; 79.1%, p < 0.001). Patients in the DMW group had significantly greater improvement (p < 0.007) in VAS walking pain by 3 weeks (following the second injection) compared to all groups. This difference was persistent at 16 weeks. Greater improvement in patients who received the DMW product was achieved by the second injection persistent at 16 weeks.
Similar content being viewed by others
References
Dieppe P (1998) Osteoarthritis. Acta Orthop Scand 69(Suppl 281):2–5
Balasz EA, Denlinger SL (1993) Viscosupplementation: a new concept in the treatment of osteoarthritis. J Rheumatol 20(Suppl 39):3–9
Altman R, Moskowitz R, Felson DT, Anderson JJ (2002) Hyaluronate sodium injections for osteoarthritis: the truth. Arch Intern Med 162:2498–2500
American College of Rheumatology Subcommittee on Osteoarthritis Guidelines (2000) Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. Arthritis Rheum 43(9):1905–1915
Dahlberg L, Lohmander LS, Ryd L (1994) Intraarticular injections of hyaluronan in patients with cartilage abnormalities and knee pain. Arthritis Rheum 37:521–528
Dougados M, Nguyen M, Listrat V, Amor B (1993) High molecular weight sodium hyaluronate (hyalectin) in osteoarthritis of the knee: a 1-year placebo-controlled trial. Osteoarthr Cartil 1:97–103
Petrella RJ, DiSilvestro MD, Hildebrand C (2002) Effects of hyaluronate sodium on pain and physical functioning in osteoarthritis of the knee. Arch Intern Med 162:292–298
Karlsson J, Sjogren LS, Lohmander LS (2002) Comparison of two hyaluronan drugs and placebo in patients with knee osteoarthritis: a controlled, randomized, double-blind, parallel-design multi-center study. Rheumatology (Oxford) 41:1240–1248
Arrol B, Goodyear-Smith F (2004) Corticosteroid injections for osteoarthritis of the knee: meta-analysis. BMJ 328:869 Epub
Leopold SS, Redd BB, Warme WJ, Wehrle PA, Pettis PD, Shott S (2003) Corticosteroid compared with hyaluronic acid injections for the treatment of osteoarthritis of the knee: a prospective, randomized trial. J Bone Joint Surg 85:1197–1203
Adams ME, Atkinson MH, Lussier AJ et al (1995) The role of viscosupplementation with hylan GF-20 (Synvisc) in the treatment of osteoarthritis of the knee: a Canadian multi-centre trial comparing hylan GF-20 alone, hylan GF-20 with non-steroidal anti-inflammatory drugs (NSAIDs) and NSAIDs alone. Osteoarthr Cartil 3:213–226
Lo GH, LaValley M, McAlindon T, Felson DT (2003) Intraarticular hyaluronic acid in the treatment of knee osteoarthritis: a meta-analysis. JAMA 290:3115–3121
Mamlin LA, Melfi CA, Parchman ML et al (1998) Management of osteoarthritis of the knee by primary care physicians. Arch Fam Med 7:563–567
Kotevoglu N, Iyibozkurt PC, Hiz O, Toktas H, Kuran B (2006) A prospective randomised controlled clinical trial comparing the efficacy of different molecular weight hyaluronan solutions in the treatment of knee osteoarthritis. Rheumatol Int 26:325–330
Kirchener M, Marshall D (2006) A double-blind randomized controlled trial comparing alternate forms of high molecular weight hyaluronan for the treatment of osteoarthritis of the knee. Osteoarthr Cartil 14:154–162
Greenberg DD, Stoker A, Kane S, Cockrell M, Cook JL (2006) Biochemical effects of two different hyaluronic acid products in a co-culture model of osteoarthritis. Osteoarthr Cartil 14:814–822
Altman RD, Fries JF, Block DA et al (1987) Radiographic assessment of progression in osteoarthritis. Arthritis Rheum 30:1214–1225
Bellamy N (1997) Osteoarthritis clinical trials: candidate variables and clinimetric properties. J Rheumatol 24:768–778
Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I (1996) Improving the quality of reporting clinical trials: the CONSORT statement. JAMA 276:637–639
Murakami T, Salai N, Sawae Y, Tanaka K, Ihara M (2004) Influence of proteoglycan on time-dependent mechanical behaviors of articular cartilage under constant total compressive deformation. JSME Int J 47:1049–1055
Ghosh P, Guidolin D (2002) Potential mechanism of action of intra-articular hyaluronan therapy in osteoarthritis: are the effects of molecular weight dependent? Semin Arthritis Rheum 32:10–37
Acknowledgements
Dr. Petrella is supported on a Canadian Institutes of Health Research Investigator Award for Healthy Lifestyle: Healthy Aging.
Author information
Authors and Affiliations
Corresponding author
Additional information
Registered Clinical trial number: ISRCTN98630331
Rights and permissions
About this article
Cite this article
Petrella, R.J., Cogliano, A. & Decaria, J. Combining two hyaluronic acids in osteoarthritis of the knee: a randomized, double-blind, placebo-controlled trial. Clin Rheumatol 27, 975–981 (2008). https://doi.org/10.1007/s10067-007-0834-4
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-007-0834-4